OMGA Stock Overview
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company.
Omega Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.56|
|52 Week High||US$31.41|
|52 Week Low||US$1.98|
|1 Month Change||4.35%|
|3 Month Change||64.03%|
|1 Year Change||-79.33%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-71.50%|
Recent News & Updates
Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M
Omega Therapeutics press release (NASDAQ:OMGA): Q2 GAAP EPS of -$0.54 in-line. Revenue of $0.48M beats by $0.43M. As of June 30, 2022, the company had cash, cash equivalents and marketable securities totaling $173.7M.
Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002
Omega Therapeutics (NASDAQ:OMGA) on Thursday said the U.S. FDA had cleared its investigational new drug (IND) application to start a phase 1/2 trial of its lead product candidate OTX-2002 for the treatment of a type of liver cancer called hepatocellular carcinoma. The company had submitted the IND to the FDA in mid-June. OMGA said the early-to-mid stage trial is expected to launch in H2 2022. The trial will evaluate the safety and preliminary antitumor activity of OTX-2002. OMGA stock fell 2.1% to $4.25 after hours.
|OMGA||US Biotechs||US Market|
Return vs Industry: OMGA underperformed the US Biotechs industry which returned -22.2% over the past year.
Return vs Market: OMGA underperformed the US Market which returned -8.9% over the past year.
|OMGA Average Weekly Movement||21.6%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: OMGA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: OMGA's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature’s operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer.
Omega Therapeutics, Inc. Fundamentals Summary
|OMGA fundamental statistics|
Is OMGA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OMGA income statement (TTM)|
|Cost of Revenue||US$60.59m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.79|
|Net Profit Margin||-9,634.50%|
How did OMGA perform over the long term?See historical performance and comparison